Brief: Oncolytics Biotech Doses First Patient In Study Of Pelareorep/FOLFIRINOX Combination Therapy In Pancreatic Cancer
20/06/2024 12:34
June 20 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® DOSES FIRST PATIENT IN STUDY OF
PELAREOREP/FOLFIRINOX COMBINATION THERAPY IN PANCREATIC CANCER
Source text for Eikon: ID:nCNWBjn2Ja
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer